临床误诊误治2025，Vol.38Issue(13)：21-25,5.DOI:10.3969/j.issn.1002-3429.2025.13.005
曲妥珠单抗联合化疗对HER2阳性转移性胃癌患者肿瘤标志物、炎症因子及不良反应的影响
Impact of Trastuzumab Combined with Chemotherapy on Tumor Markers,Inflammatory Factors and Adverse Reactions in Patients with HER2-positive Metastatic Gastric Cancer
摘要
Abstract
Objective To investigate the impact of combination of Trastuzumab and chemotherapy on tumor markers,in-flammatory factors and adverse reactions in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic gastric cancer.Methods A total of 120 patients with HER2-positive metastatic gastric cancer were collected from September 2021 to October 2023.According to different treatment regimens,they were divided into chemotherapy group(n=58,conventional chemo-therapy)and monoclonal antibody group(n=62,Trastuzumab combined with chemotherapy).The clinical effect,tumor markers,inflammatory factors and occurrence of adverse reactions were compared between the two groups.Both groups were followed up for 1 year,and the median overall survival time was recorded in the two groups.Results The disease control rate in monoclo-nal antibody group was higher than that in chemotherapy group(P<0.05).After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 19-9,carbohydrate antigen 72-4,monocyte chemoattractant protein-1,interleukin-1β,and C-X-C motif chemokine ligand 10 in the two groups were decreased,and the above levels in monoclonal antibody group were lower than those in chemotherapy group(P<0.05).There were no differences in the incidence rates of adverse reactions such as hematolog-ical toxicity,gastrointestinal reaction,liver-kidney function damage and cardiac toxicity between groups(P>0.05).The median overall survival time was 14.2 months(95%CI:12.8,15.6)in monoclonal antibody group and 11.5 months(95%CI:10.2,12.8)in chemotherapy group(P<0.05).Conclusion Trastuzumab combined with chemotherapy has good effects in the treatment of HER2-positive metastatic gastric cancer.It can effectively reduce the tumor markers,relieve the inflammatory response,and pro-long the survival time in patients with HER2-positive metastatic gastric cancer,with high safety.关键词
胃肿瘤/人表皮生长因子受体2/转移/曲妥珠单抗/糖类抗原19-9/白细胞介素-1β/不良反应Key words
Stomach neoplasms/Human epidermal growth factor receptor 2/Metastasis/Trastuzumab/Carbohydrate antigen 19-9/Interleukin-1β/Adverse reaction分类
医药卫生引用本文复制引用
孙建璞,张倩,王学智,王萌,卢旭东,任冬飞..曲妥珠单抗联合化疗对HER2阳性转移性胃癌患者肿瘤标志物、炎症因子及不良反应的影响[J].临床误诊误治,2025,38(13):21-25,5.基金项目
河北省2023年度医学科学研究课题(20231193) （20231193）
